Fund moves
0.0%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
EVO · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Evotec (EVO) · oqro.io/stocks/EVO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.32−0.13 (−8.97%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Evotec is on record in SEC filings since 2006.
No open-market sale by an insider of Evotec (EVO) was filed with the SEC in the last 90 days.
No trade in Evotec (EVO) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−54.5% (−$1.58) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $2.90 on Nov 20, 2025 to $1.32 on Nov 20, 2026 (−54.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Hamburg, Germany. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−54.5%
Market value
$469M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 63K shares sold short (0.0% of shares outstanding), −17.2% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Nobody is above 5% on the latest filings: every recent filer has reported going below the line.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Latest annual report filed Apr 8, 2026, compared with the one filed Apr 17, 2025. Read the filing
Source: SEC EDGAR, Form 20-F filed Apr 8, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 52.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (9.9% on ATS, 42.4% with other brokers), above its 26-week average of 47.6%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: BOATS (25.5%), INTELLIGENT CROSS LLC (13.9%), SIGMA X2 (9.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Apr 8, 2026. Figures are in EUR, the currency of the filing. Read the filing
−13% on the year before (611M EUR). Operating income −74.5M EUR, a −14% margin
+40% on the year before (186M EUR). Operating income 18.3M EUR, a 7% margin
−17% on the year before (737M EUR)
+3809% on the year before (3.13M EUR)
−17% on the year before (38.6M EUR)
+235% on the year before (2.87M EUR)
−45% on the year before (544K EUR)
−3.2% on the year before (446M EUR)
+48% on the year before (109M EUR)
−6.3% on the year before (82.3M EUR)
−33% on the year before (92.5M EUR)
−23% on the year before (32.9M EUR)
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 9,000 words.
We generate revenue primarily through three core collaboration routes: (1) by providing our drug discovery and development capabilities on a fee-for-service and FTE-rate basis; (2) by receiving milestones and royalties on partnered assets; and (3) by creating value through equity ownership in emerging, highly innovative biotechnology companies and translational academic institutional projects. Contracts with our partners can include elements of one or more of our three core collaboration routes. Until December 31, 2023, we reported the results of our operations in two operating segments: EVT Execute and EVT Innovate.
Source: SEC EDGAR, Form 20-F filed Apr 8, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
−0.3% on the year before (19.9M EUR)
And 26 more headings in the filing.
Against the S&P 500 over the year
Since Nov 18, 2025, EVO is down 55.4% and the index fund is up 4.5%: 60 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much EVO moves
Beta 1.2 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).